OKYO Pharma OKYO Institutional Ownership

Ownership Summary

OKYO Pharma Ltd (NASDAQ:OKYO) showed up in the 13F filings of 12 institutional investors as of March 2026.

• These investors held 16.2% of outstanding shares in March 2026, up from 1.7% in December 2025.
• Their total shares held in OKYO increased 1135.22% quarter over quarter, and separately, investors owning OKYO Pharma increased 50.0% from a year ago.
• Of these 12 funds, 6 grew their exposure to OKYO Pharma, 1 cut back, and 5 maintained positions.
• In total, institutional investors held 6.39Mn shares in OKYO Pharma as of March 2026, up by 5.87Mn shares quarter on quarter, and up 4.31Mn shares year over year.
• As of March 31, 2026, Woodline Partners LP held the largest stake in OKYO Pharma with 3.65Mn shares, accounting for 9.25% of total shares outstanding.
• The most significant purchases of OKYO for the quarter ending March 2026 came from Woodline Partners LP (3.65Mn), Maven Securities LTD (1.18Mn), Stonepine Capital Management, LLC (850.0K), BALYASNY ASSET MANAGEMENT L.P. (584.8K), UBS Group AG (57.59K).
• Leading sellers of OKYO Pharma shares for the quarter ending March 2026 were Dauntless Investment Group, LLC (467.7K).
• Per Business Quant, the top 10 investors in OKYO for the quarter ending March 2026 include Woodline Partners LP (3.65Mn), Maven Securities LTD (1.18Mn), Stonepine Capital Management, LLC (850.0K), BALYASNY ASSET MANAGEMENT L.P. (584.8K), UBS Group AG (59.76K), XTX Topco Ltd (37.65K), Cerity Partners LLC (12.81K), GEODE CAPITAL MANAGEMENT, LLC (12.09K), Dauntless Investment Group, LLC (3.82K), EFG International AG (923).